NEW YORK, May 8 – Saiid Zarrabian, who resigned as chief operating officer at Pharmacopeia in December, has been appointed president and COO of Senomyx, a developer of flavor and fragrance molecules that can be used in consumer products, Senomyx said Tuesday.

"Mr. Zarrabian brings tremendous knowledge to Senomyx, particularly in the area of chemical and biological simulations and analysis systems, as well as drug discovery process,” Senomyx CEO Paul Grayson said in a statement.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.